MedTrace Logo

COVID-19 Seroprevalence Study in French Guiana

NCT04490850 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3541

Last updated 2022-02-15

No results posted yet for this study

Summary

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

Conditions

  • Coronavirus Infection
  • Severe Acute Respiratory Syndrome
  • SARS-CoV Infection
  • Covid19

Interventions

PROCEDURE

Blood sample

Blood sample

Sponsors & Collaborators

  • Institut Pasteur de la Guyane

    collaborator UNKNOWN

  • Laboratoire de biologie médicale, Institut Pasteur de la Guyane

    collaborator UNKNOWN

  • Laboratoire de biologie médicale de Kourou, French Guiana

    collaborator UNKNOWN

  • Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana

    collaborator UNKNOWN

  • Eurofins

    collaborator INDUSTRY

  • Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana

    collaborator UNKNOWN

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Claude Flamand, PhD · Institut Pasteur de la Guyane, Head of Epidemiology Unit

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2021-09-24
Completion
2021-09-24

Countries

  • French Guiana

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04490850 on ClinicalTrials.gov